RJ
Therapeutic Areas
Soligenix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HyBryte™ (SGX301) | Cutaneous T-Cell Lymphoma (CTCL) | Phase 3 |
| SGX301 | Cutaneous T-Cell Lymphoma (CTCL) - First-Line | Phase 2b |
| Dusquetide (SGX942) | Oral Mucositis in Head & Neck Cancer | Phase 2/3 |
| SGX945 (Dusquetide) | Behçet's Disease | Preclinical |
| RiVax® | Ricin Toxin Poisoning (Prevention) | Phase 1b |
| SGX203 | Pediatric Crohn's Disease | Phase 2/3 |
| SGX202 | Acute Radiation Syndrome (GI-ARS) | Phase 1/2 |
| CiVax™ | COVID-19 (SARS-CoV-2) | Preclinical |
Leadership Team at Soligenix
CJ
Christopher J. Schaber
Chairman, President & Chief Executive Officer
JG
Jonathan Guarino
Senior Vice President & Chief Financial Officer
OD
Oreola Donini
Senior Vice President & Chief Scientific Officer
RS
Richard Straube
Senior Vice President & Chief Medical Officer
DL
Diane L. Parks
Director
JB
Jerome B. Zeldis
Director